Inventor

COATES DAVID ANDREW

US31 patents

⚠️ This page may combine multiple inventors who share the name “COATES DAVID ANDREW”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

COATES DAVID ANDREW

LILLY CO ELI

Amino pyrimidine SSAO inhibitors

3,4-dihydroisoquinolin-2(1H)-yl compounds

SSTR4 agonist salts

Amino pyrimidine ssao inhibitors

Amino pyrimidine SSAO inhibitors

Disubstituted pyrazole compounds

CGRP receptor antagonists

KRas G12C inhibitors

Tetrahydropyrrolo[3,4-D][1,3]thiazine-derivative as BACE inhibitor

CGRP receptor antagonists

SSTR4 agonist salts

CGRP receptor antagonists

Disubstituted pyrazole compounds

Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate

Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate

Dopamine D1 receptor positive allosteric modulators

Glucagon-like peptide1 receptor agonists

IL-17A inhibitors

Solid forms of 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one

Pyrazolylaminobenzimidazole derivatives as JAK inhibitors

Tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide

Condensed thiophene derivatives useful as NaPi-IIb inhibitors

2-oxo-1,3,8-triazaspiro[4.5]decan-3-yl] carboxylic acid derivatives

(E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7

WARNER LAMBERT CO

Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

EATON INTELLIGENT POWER LTD

Electroacoustic driver and related loudspeaker/sounder

Electroacoustic driver housing element

COATES DAVID ANDREW

Mineralocorticoid receptor antagonist and methods of use

Oxazolo[5-4-b]pyridin-5-yl compounds

CAMP ANNE MARIE

Substituted [(5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists

Crystalline forms of [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

Crystalline forms of [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)